Hormone Replacement Therapy Market

Hormone Replacement Therapy Market Outlook 2024 to 2034

The hormone replacement therapy market is expected to expand at a CAGR of 3.5%. The market value is projected to increase from USD 16,825.2 million in 2024 to USD 23,729.6 million by 2034. The hormone replacement therapy industry share was valued at USD 15,976.9 million at the end of 2023.

Attributes	Details
Estimated Market Size, 2024	USD 16,825.2 million
Expected Market Share, 2034	USD 23,729.6 million
Value CAGR (2024 to 2034)	3.50%

Top Trends in Impacting Use of Hormone Replacement Therapy

• Leading manufacturers are launching new formulations in the market, including gels, transdermal drugs, and creams. The underlying reason behind these developments is wide adoption among the masses. Furthermore, players are also introducing a new long-acting growth hormone injection to their portfolio.
• Changing the perception of HRT in medical societies as they support appropriate doses for a suitable amount of time is also increasing acceptance of HRT.
• Surging demand for advanced patient care is opening doors for manufacturers of hormone replacement therapy.
• Common use of hormone replacement therapy (HRT) is in the treatment of menopausal disorder. Growing knowledge about postmenopausal problems among females is also favoring market growth.
• Prominent market players are investing in the innovation of HRT to enhance patient’s quality of life. Healthcare professionals usually prescribe hormone therapy to treat the genitourinary syndrome of menopause and vasomotor symptoms (VMS). Such broad adoption of HRT to prevent fracture and bone loss is projected to propel market growth.
• Patients are showing active participation in managing their disorders. As a result, the choice to use HRT has become personalized, catering to potential risk factors and women’s needs.

Analysis of Historical and Future Outlooks of the Hormone Replacement Therapy Market

Attributes	Details
Hormone Replacement Therapy Market Value (2019)	USD 13,059.1 million
Hormone Replacement Therapy Market Size (2023)	USD 15,976.9 million
Historical CAGR % (2019 to 2023)	4.1%

The hormone replacement therapy (HRT) market expanded at a CAGR of 4.1% from 2019 to 2023. Meanwhile, the market surged from USD 13,059.1 million in 2019 to USD 15,976.9 million in 2023. The market is driven by a robust healthcare system in developed countries and increasing medical tourism. Other leading factors that have reinforced market competition in the previous period include:

• Consistent advances in hormone replacement therapy are offered by leading market players.
• Surging female population reaching the age of menopause.
• Increasing efforts by leading players to obtain approval from regulatory bodies, for instance, the FDA in the United States.

From 2024 to 2034, the market is projected to register a CAGR of 3.5%. The market is projected to capture a market size of USD 16,825.2 million in 2024. By 2034, the market valuation is anticipated to be USD 23,729.6 million. Top factors that are contributing to market growth are as follows:

• Growing demand for regenerative medicines like reproductive-cycle boosting and antiaging therapy.
• Rising efforts on the part of players to increase the efficiency, cost-efficiency, and safety profile of these therapies are propelling market growth.
• Surging research and development efforts by leading companies to develop novel formulations for patient care.

Historical CAGR % (2019 to 2023)	4.1%
Forecast CAGR % (2024 to 2034)	3.5%

Category-wise Insights

Estrogen Replacement Therapy to Account for a Sizeable Market Portion

Leading Therapy Area	Estrogen Replacement Therapy
Value Share % (2024)	38.9%

The estrogen replacement therapy (ERT) segment is projected to account for a share of 38.9% in 2024. The segment is anticipated to capture an increased female population experiencing falling levels of estrogen and progesterone. Change in hormone secretion, typically caused during menopause, also derails the quality of life. Thus, patients of menopause are being prescribed estrogen replacement therapy to reduce impact of falling hormones.

This segment is further projected to grow due to several women entering the stage of menopause. Increasing demographic of menopausal women is expected to raise the consumption of ERT in the next ten years.

Oral Tablets/Capsules Poised for Significant Growth in the Future

Leading Dosage Form	Oral Tablets/Capsules
Value Share % (2024)	43.2%

Oral tablets/capsules segment is anticipated to acquire a share of 43.2% in 2024. Oral dosage is gaining significant traction due to its convenience. Several patients, especially those who are senior or have a hard time with other routes of administration, prefer oral medications.

Their higher uptake also hinges on the fact that it is cost-effective and demonstrates effective absorption. Additionally, oral capsules or tablets have formed a well-established safety profile over the years. Thus increasing its acceptance among doctors and patients.

Country-wise Insights

Market Scope of Hormone Replacement Therapy in the United States

Country	The United States
Forecast CAGR % (2024 to 2034)	1.6%

The hormone replacement therapy market in the United States is anticipated to register a CAGR of 1.6% through 2034. Sluggish adoption of this medication points toward market maturity attained by the United States. To break into this country, key players are projected to strive forward massively. Key factors propelling growth in the United States are as follows:

• Early onset of aging coupled with high disposable income.
• The rising frequency of product launches, contractual agreements with manufacturers, and supportive reimbursement policies are pushing market players for higher market gains.

Opportunities for Market Players in the United Kingdom

Country	The United Kingdom
Forecast CAGR % (2024 to 2034)	2.3%

As per recent market estimates, the United Kingdom is assessed to expand at a CAGR of 2.3% through 2034. The country is anticipated to be driven by:

• Increasing geriatric population within the United Kingdom.
• Rising campaigns aimed at dispensing awareness about postmenopausal hormone therapy.
• Robust healthcare system in the country.

Market Outlook for Hormone Replacement Therapies in Germany

Country	Germany
Forecast CAGR % (2024 to 2034)	2.1%

In Germany, the demand for hormone replacement therapies is anticipated to increase at a CAGR of 2.1% through 2034. The market is driven by the following factors:

• Surging cases of hormonal disorders in Germany are complementing the sales of hormone replacement therapies.
• Key players are developing novel drug delivery systems to target populations suffering from hormone imbalance issues.

Lucrative Prospects for Hormone Replacement Therapy in China

Country	China
Forecast CAGR % (2024 to 2034)	4.5%

As per the latest market research by FMI analysts and industry experts, the China hormone replacement therapy market is projected to expand at a CAGR of 4.5% through 2034. The following factors are supporting market growth in the country:

• An increasing count of manufacturers are investing in the Chinese economy to capture the massive population suffering from menopausal symptoms. With the rapidly growing elderly population in China, the demand for associated medications is expected to rise.
• Leading players are developing products with novel formulations. These formulations are proven for their effective and improved results.

These aforementioned factors are projected to consolidate the market position in China. Constant innovations and target markets in China are anticipated to propel significant market expansion.

Manufacturers are Eyeing India Due to Profitable Prospects for Hormone Replacement Therapy Industry

Country	India
Forecast CAGR % (2024 to 2034)	5.2%

Manufacturers are expected to obtain significant growth opportunities in India. FMI analysts have estimated that the market in India is going to rise at a CAGR of 5.2% through 2034. Crucial factors that are augmenting the uptake of hormone replacement therapy in India are as follows:

• Rising incidence rate of hormone deficiency disorders in India.
• Key players are expanding into India to drastically increase their consumer base and enjoy volume sales.
• Growing patient base for gender reassignment procedures undertaken by transgenders in India. This is increasing the uptake of hormone replacement therapy for gender reassignments in the country.

Key Players are Scheming for Success in the Hormone Replacement Therapy Market

Key players are strategically collaborating within the hormone replacement therapy market to position themselves for success. Players are further investing in research and development activities to enhance the efficacy of these therapies and increase consumer confidence. Additionally, market participants are attempting to obtain patents and product approvals to expand their portfolio.

Market participants are further partnering with other players or social media influencers to increase awareness about postmenopausal problems. This is anticipated to raise consumer knowledge about various options available to them.

To increase product adoption, manufacturers are launching hormone replacement products in user-friendly, distinct formats like patches and pills. Market leaders are also traversing boundaries to reach more customers.

New Developments Giving Shape to the Hormone Replacement Therapy Market

• In June 2023, Pfizer’s NGENLA received FDA approval. The product acts as a long-acting once-weekly treatment for patients suffering from pediatric growth hormone deficiency. In August 2023, NGENLA became available in the United States.
• In April 2023, Novo Nordisk reported that it had gained FDA approval for a new indication of Sogroya. These indications are intended for +2.5-year-old children who suffer from growth failure caused by insufficient endogenous growth hormone secretion.

Prominent Companies in the Hormone Replacement Therapy Market are as Follows

• Eli Lilly and Company
• Bayer AG
• Noven Pharmaceuticals, Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Viatris, Inc.
• Novo Nordisk A/S
• F. Hoffmann-La Roche Ltd.
• ASCEND Therapeutics US, LLC.
• AbbVie, Inc.
• Others

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
• 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Type
  • 5.1. Estrogenic Replacement Therapy
  • 5.2. Growth Hormone Replacement
  • 5.3. Dopamine Agonist
  • 5.4. Somatostatin Analogues
  • 5.5. Thyroid Hormone Replacement
  • 5.6. Tablets
  • 5.7. Capsules
  • 5.8. Injections
• 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
  • 6.1. Cancer
  • 6.2. Menopause
  • 6.3. Hypopituitarism
  • 6.4. Hypothyroidism
  • 6.5. Others
• 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
  • 7.1. Hospital Pharmacies
  • 7.2. Retail Pharmacies and Drugstores
  • 7.3. Compounding Pharmacies
  • 7.4. E-commerce
  • 7.5. Others
• 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
  • 8.1. North America
  • 8.2. Latin America
  • 8.3. Western Europe
  • 8.4. Eastern Europe
  • 8.5. South Asia and Pacific
  • 8.6. East Asia
  • 8.7. Middle East and Africa
• 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 16. Key Countries Market Analysis
• 17. Market Structure Analysis
• 18. Competition Analysis
  • 18.1. Eli Lilly and Company
  • 18.2. Pfizer, Inc.
  • 18.3. AbbVie, Inc.
  • 18.4. Endo International
  • 18.5. Merck KGaA
  • 18.6. Mylan N.V.
  • 18.7. Bayer Healthcare
  • 18.8. F. Hoffmann-La Roche Ltd.
  • 18.9. Teva Pharmaceuticals
  • 18.10. Novo Nordisk A/S
• 19. Assumptions & Acronyms Used
• 20. Research Methodology